To Evaluate Safety and Tolerability After Multiple Oral Doses of AZD1656 in Type 2 Diabetes Patients on Top of Insulin

Launched by ASTRAZENECA · Oct 6, 2008

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Female with non child-bearing potential
• • Diagnosed Diabetes Mellitus patients treated with insulin alone or insulin in combination with other anti-diabetic drugs. Stable blood sugar control indicated by no changed treatment within 3 months prior to study start.
• • HbA1c below or equal to 11 % at screening (HbA1c value according to international DCCT standard)
• Exclusion Criteria:
• • Clinically significant illness or clinically relevant trauma, as judged by the investigator, within two weeks before the first administration of the IP
• • History of ischemic heart disease, stroke, transitorisk ischemic attack or symptomatic peripheral vascular disease
• • Clinically significant abnormalities in clinical chemistry, hematology, or urinalysis results.